1-20 of 54
molecular targeted therapy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal residual disease and stem cell transplantation outcomes

Jacqueline Cloos, Gert J. Ossenkoppele, Richard Dillon
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 617–625.
https://doi.org/10.1182/hematology.2019000006
Published: 2019
Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Jennifer A. Woyach
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 476–481.
https://doi.org/10.1182/hematology.2019001321
Published: 2019
Journal Articles

Where does transplant fit in the age of targeted therapies?

Victor A. Chow, Ajay K. Gopal
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 287–293.
https://doi.org/10.1182/hematology.2019000033
Published: 2019
Journal Articles

Treatments targeting MDS genetics: a fool’s errand?

Amy E. DeZern
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 277–285.
https://doi.org/10.1182/asheducation-2018.1.277
Published: 2018
Journal Articles

Challenges and implications of genomics for T-cell lymphomas

Eric D. Jacobsen, David M. Weinstock
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 63–68.
https://doi.org/10.1182/asheducation-2018.1.63
Published: 2018
Journal Articles

New drugs for acute myeloid leukemia inspired by genomics and when to use them

Daniel A. Pollyea
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 45–50.
https://doi.org/10.1182/asheducation-2018.1.45
Published: 2018
Journal Articles

Relapsed CLL: sequencing, combinations, and novel agents

Jennifer R. Brown
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 248–255.
https://doi.org/10.1182/asheducation-2018.1.248
Published: 2018
Journal Articles

AL amyloidosis: from molecular mechanisms to targeted therapies

Giampaolo Merlini
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 1–12.
https://doi.org/10.1182/asheducation-2017.1.1
Published: 2017
Journal Articles

Progress in adult ALL: incorporation of new agents to frontline treatment

Jessica Leonard, Wendy Stock
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 28–36.
https://doi.org/10.1182/asheducation-2017.1.28
Published: 2017
Journal Articles

The role of targeted therapy in the management of patients with AML

Alexander E. Perl
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 54–65.
https://doi.org/10.1182/asheducation-2017.1.54
Published: 2017
Journal Articles

Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age

Jaroslaw P. Maciejewski, Suresh K. Balasubramanian
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 66–72.
https://doi.org/10.1182/asheducation-2017.1.66
Published: 2017
Journal Articles

Prognostication of chronic lymphocytic leukemia in the era of new agents

Barbara Eichhorst, Michael Hallek
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 149–155.
https://doi.org/10.1182/asheducation-2016.1.149
Published: 2016
Journal Articles

Prognostic factors in follicular lymphoma: new tools to personalize risk

Carla Casulo
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 269–276.
https://doi.org/10.1182/asheducation-2016.1.269
Published: 2016
Journal Articles

First-line therapy for young patients with CLL

Nitin Jain, Susan O’Brien
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 146–148.
https://doi.org/10.1182/asheducation-2016.1.146
Published: 2016
Journal Articles

Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition

Oussama Abla, Sheila Weitzman
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 565–570.
https://doi.org/10.1182/asheducation.V2015.1.565.3919688
Published: 2015
Journal Articles

Uncommon histiocytic disorders: Rosai–Dorfman, juvenile xanthogranuloma, and Erdheim–Chester disease

Julien Haroche, Oussama Abla
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 571–578.
https://doi.org/10.1182/asheducation.V2015.1.571.3916289
Published: 2015
Journal Articles

Advances in therapies for non-Hodgkin lymphoma in children

Rachel Kobos, William Terry
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 522–528.
https://doi.org/10.1182/asheducation.V2015.1.522.3916185
Published: 2015
Journal Articles

Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies

E. Anders Kolb, Soheil Meshinchi
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 507–513.
https://doi.org/10.1182/asheducation-2015.1.507
Published: 2015
Journal Articles

Molecularly targeted therapies for acute myeloid leukemia

Eytan M. Stein
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 579–583.
https://doi.org/10.1182/asheducation-2015.1.579
Published: 2015
Journal Articles

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Amy E. DeZern
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 308–316.
https://doi.org/10.1182/asheducation-2015.1.308
Published: 2015